ANO1 and cystic fibrosis: Its abnormal expression is involved in the pathology of various diseases, including asthma, diarrhea, cystic fibrosis, hypertension, ischemic stroke, and cancer.[34] As a result, both CFTR and ANO1 are considered emerging therapeutic targets for diarrhea and other epithelium‐originated diseases, and some inhibitors are currently under clinical trials.[34, 35] In our study, we observed increased levels of Cftr and Ano1 in mouse small intestine, colon, and gut organoids after T‐bet overexpression, consistent with the diarrhea and dehydration phenotypes.